Navigation Links
Arena Pharmaceuticals Announces Positive Lorcaserin Pivotal Phase 3 Obesity Trial Results: Meets All Primary Efficacy and Safety Endpoints
Date:3/30/2009

diabetes; future activities, results and announcements relating to lorcaserin, including the BLOSSOM results, the submission of an NDA for lorcaserin and the submission of the BLOOM-DM results as a supplement to the NDA; the potential of lorcaserin to meet the FDA's requirements for approval and the approval of lorcaserin for marketing; commercialization options and the coverage of lorcaserin patents; and about Arena's strategy, internal and partnered programs, and ability to develop compounds and commercialize drugs. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, Arena's ability to obtain additional funds, the timing, success and cost of Arena's lorcaserin program and other of its research and development programs, the results of clinical trials or preclinical studies may not be predictive of future results, clinical trials and studies may not proceed at the time or in the manner Arena expects or at all, Arena's ability to partner lorcaserin or other of its compounds or programs, the timing and ability of Arena to receive regulatory approval for its drug candidates, Arena's ability to obtain and defend its patents, and the timing and receipt of payments and fees, if any, from Arena's collaborators. Additional factors that could cause actual results to differ materially from those stated or implied by Arena's forward-looking statements are disclosed in Arena's filings with the Securities and Exchange Commission. These forward-looking statements represent Arena's judgment as of the time of this release. Arena disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.

    Contacts:   Jack Lief                          
'/>"/>
SOURCE Arena Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine news :

1. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
2. Arena Pharmaceuticals Announces Public Offering of Common Stock
3. Arena Pharmaceuticals to Present at the BIOCOM Investor Conference
4. Arena Pharmaceuticals Announces Pricing of Public Offering of Common Stock
5. Arena Pharmaceuticals to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
6. Arena Pharmaceuticals Lorcaserin for Obesity Passes Major Safety Milestone
7. Arena Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Unplugged Conference
8. Arena Pharmaceuticals to Report First Quarter 2008 Financial Results and to Host Conference Call and Webcast on Wednesday, May 7, 2008
9. Field Poll: California Nurses Association Most Favorably Viewed Group in Healthcare Arena
10. Childrens Miracle Network and Arena Football League Partner for First Nationwide Celebration Event
11. Arena Pharmaceuticals Announces Third Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/20/2014)... December 20, 2014 As Risperdal ... forward in U.S. courts, Bernstein Liebhard LLP notes ... that children treated with the medication may experience ... breast development and lactation. The study, which appears ... and adolescents who began treatment with risperidone, an ...
(Date:12/20/2014)... The aftermath of the November 24th hack on Sony ... Hollywood, but worldwide. As reported in the Los ... attack are starting a finger-pointing game which could put some ... are not the only ones affected, regular employees who had ... times ahead, agents and lawyers could be in for some ...
(Date:12/20/2014)... 20, 2014 Developers of FCPX ... a new plugin for Final Cut Pro X entitled ... Volume 5 allows users to create hand drawn text ... Christina Austin, CEO of Pixel Film Studios. “TranSlice Volume ... while maintaining an easy to use interface.” , TranSlice ...
(Date:12/20/2014)... 20, 2014 The Twin Cities DI ... event in the nation! Over 250 financial professionals come ... information on the industry, get motivated to protect their ... people facing and overcoming the challenges of disability. , ... the nation came together to attend The 13th Annual ...
(Date:12/20/2014)... Today, Balfleet.com, one of the most outstanding dressmakers in ... on its Mother of the Bride Dresses ... bride dresses from Balfleet.com feature gorgeous looks and delicate ... pride in providing high quality dresses to its clients ... on our mother of the bride dresses, and we ...
Breaking Medicine News(10 mins):Health News:Risperdal Lawsuit News: Bernstein Liebhard LLP Notes Publication of Study Suggesting Medication May Raise Prolactin Levels in Children 2Health News:Risperdal Lawsuit News: Bernstein Liebhard LLP Notes Publication of Study Suggesting Medication May Raise Prolactin Levels in Children 3Health News:Risperdal Lawsuit News: Bernstein Liebhard LLP Notes Publication of Study Suggesting Medication May Raise Prolactin Levels in Children 4Health News:Sony Pictures Hack Perfect Example of the Reach a Single Cyber Attack Can Have 2Health News:Sony Pictures Hack Perfect Example of the Reach a Single Cyber Attack Can Have 3Health News:Sony Pictures Hack Perfect Example of the Reach a Single Cyber Attack Can Have 4Health News:Sony Pictures Hack Perfect Example of the Reach a Single Cyber Attack Can Have 5Health News:Pixel Film Studios released a new transition entitled TranSlice Volume 5 exclusively for Final Cut Pro X 2Health News:The 13th Annual Twin Cities DI Day Now On Video 2Health News:The 13th Annual Twin Cities DI Day Now On Video 3Health News:Balfleet.com is Offering 50%-70% Off of its Mother of the Bride Dresses 2
... or no sunscreen in spite of staying under direct sunlight ... sports spend a significant amount of time practicing and competing ... they are spending so much time in the sun, they ... of them regularly use any form of sunscreen, according to ...
... Immunization (IFFIm) will be providing life saving vaccines for ... project costing $4 billion to be funded by the ... the scheme, the International Finance Facility for Immunization (IFF), ... over the next 10 years and another five million ...
... daily stress in their life have less risk of developing ... in the British Medical Journal. The study was conducted in ... The estrogen which is responsible for growth ... have found that stress reduced the production of oestrogen and ...
... In a study, published in the recent issue of The ... Hospital, Michigan, had concluded that obesity is a risk factor ... are below the age of 40years.// ,Since 1927, ... fatal pulmonary embolism (PE). Because of the high proportion of ...
... a married couple in West Bengal. The duo preferred to ... everyday. ,In an act driven// by social ostracism, a 29-year-old ... hanged himself in the Durgapur industrial town of south Bengal's ... Sarkar were a happy couple since their love marriage four ...
... in people may accelerate the heart conditions by releasing the ... study of 32 people with heart failure, the 14 patients ... of this protein in their blood. ,The protein, tumor ... family of proteins called cytokines, chemical messengers that are mobilized ...
Cached Medicine News:Health News:People Still Neglect To Use Sunscreen In Spite Of Cancer Warnings 2Health News:European Countries To Fund $4 Billion For Vaccination For Poor Children’ 2
(Date:12/19/2014)... , Dec. 18, 2014 Somewhere between ... hearing health was forgotten. But Audicus , a ... hear better this new year. Hearing loss ... the aging population, though it is often unaddressed. Forty-eight ... four has a hearing aid, mainly due to price. ...
(Date:12/19/2014)... CITY, Calif., Dec. 18, 2014 Capnia, ... the development of medical diagnostics based on its ... gas flow, today announced financial results for the ... 2014. "Following the completion of our ... positioned to maximize the recently initiated CoSense® commercial ...
(Date:12/19/2014)... , Dec. 18, 2014   Aratana Therapeutics, ... biopharmaceutical company focused on the licensing, development and ... announced positive results from its pivotal field study ... treating pain in dogs with osteoarthritis.  In the ... assessment scores that were statistically significant compared to ...
Breaking Medicine Technology:Audicus Will Help People Resolve to Hear Better in 2015 2Capnia Reports Third Quarter 2014 Financial Results 2Capnia Reports Third Quarter 2014 Financial Results 3Capnia Reports Third Quarter 2014 Financial Results 4Capnia Reports Third Quarter 2014 Financial Results 5Capnia Reports Third Quarter 2014 Financial Results 6Capnia Reports Third Quarter 2014 Financial Results 7Capnia Reports Third Quarter 2014 Financial Results 8Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 2Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 3Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 4Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 5
... , , , ... majority-owned subsidiary of Speedus Corp. (Nasdaq: SPDE ), ... the U.S. FDA, has cleared the Zargis Cardioscan(TM) device ... analysis software connects wirelessly to a Bluetooth®-enabled electronic stethoscope ...
... NATICK, Mass., Jan. 8 Boston Scientific Corporation (NYSE: ... from the Japanese Ministry of Health, Labor and Welfare (MHLW) ... treatment of coronary artery disease. The Company plans to ... which is expected in the coming weeks. , The PROMUS ...
Cached Medicine Technology:Zargis Cardioscan Cleared for Sale in Canada 2Zargis Cardioscan Cleared for Sale in Canada 3Boston Scientific Announces Japanese Approval for PROMUS(R) Everolimus-Eluting Coronary Stent System 2Boston Scientific Announces Japanese Approval for PROMUS(R) Everolimus-Eluting Coronary Stent System 3Boston Scientific Announces Japanese Approval for PROMUS(R) Everolimus-Eluting Coronary Stent System 4
... nebulizer system offers an affordable and ... COPD or other respiratory conditions. The ... gives patients the ability to take ... Its unique nebulizer design delivers powerful ...
Pediatric Compressor Nubulizer...
... very popular and competitively priced SportNeb ... compressor. Design enhancements include a neb ... optional black carry bag. The color ... The SportNeb also offers private labeling ...
... is an important part of managing the ... convenient products mean delivering the aerosolized medication ... while minimizing medication waste. Aerosol delivery with ... of Nebulizers, including the new NebuTech® HDN®, ...
Medicine Products: